Inventors:
Sachin S. Chandran - Highland Park NJ, US
Sangeeta Ray - Ellicott City MD, US
Martin G. Pomper - Baltimore MD, US
Samuel R. Denmeade - Ellicott City MD, US
Ronnie C. Mease - Fairfax VA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 9/14, A61K 48/00, A61K 38/02, A61K 31/70, A61K 38/14, A61P 35/00, A61P 35/04, A61P 35/02, A61P 29/00, A61P 17/06, A61P 17/02, A61P 17/00, A61P 37/08, A61P 25/00, A61P 11/06, A61P 11/00, A61P 9/00, A61P 9/10, A61P 7/02, A61P 9/12, A61P 1/00, A61P 1/04, A61P 31/04, A61P 31/12, A61P 31/18, A61P 31/22, A61P 31/16, A61P 37/06, A61P 19/10, A61P 25/28, A61P 25/16, A61P 25/02, B82Y 5/00
US Classification:
424489, 514 44 R, 514 11, 514 23, 514 209, 977773, 977906
Abstract:
The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.